Measure nephrotoxicity using FDA and EMA-supported renal biomarkers KIM-1, Clusterin, and NGAL.
This in vitro approach is useful for investigating renal drug handling, identifying drug–transporter interactions, potential nephrotoxicity and transporter-mediated, drug–drug interactions. Source